Mixed Phenotype Acute Leukemia Clinical Trial
Official title:
A Dose-Finding Phase Ib Study of the Oral BCL-2 Inhibitor Venetoclax (ABT-199) in Combination With Standard Induction Therapy, Dasatinib, Prednisone, (and Rituximab in CD20+ Patients) in Adult Patients With Newly Diagnosed and Relapsed Philadelphia Chromosome Positive ALL (Ph+ ALL) and Ph+ MPAL
This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is newly diagnosed or that has come back (relapsed). Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab and blinatumomab are monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving venetoclax in combination with dasatinib, prednisone, and rituximab and blinatumomab may help treat patients with newly diagnosed or relapsed Philadelphia chromosome positive acute lymphoblastic leukemia.
PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) and/or a recommended phase II dose (RP2D) of venetoclax in combination with dasatinib. II. Evaluate the safety of venetoclax in combination with dasatinib by assessing the frequency, type, and severity of adverse events. SECONDARY OBJECTIVES: I. Assess preliminary response to venetoclax in combination with dasatinib based on minimal residual disease (MRD) negativity. II. Estimate progression-free and overall survival. EXPLORATORY OBJECTIVES: I. Evaluate the distribution of BCR-ABL fusion sub-types. II. Assess changes in BCL-family dependence. III. Presence of co-occurring leukemia-specific mutations. IV. Assess ex vivo sensitivity to venetoclax and dasatinib using inhibitor plates and colorimetric cell viability (MTS) assay. OUTLINE: This is dose-escalation study of venetoclax. INDUCTION PHASE CYCLE 1: Patients receive prednisone orally (PO) once daily (QD) on days -6 to 21 and rapid taper from days 22-28, dasatinib PO QD days 1-28, venetoclax PO QD days 3-28 or days 3-21, rituximab (for CD20+ patients) intravenously (IV) on days 8 and 15, and methotrexate intrathecally (IT) once during week 1 and once during week 3 in the absence of disease progression or unacceptable toxicity. INDUCTION PHASE CYCLES 2-3: Patients receive dasatinib PO QD days 1-28, venetoclax PO QD on days 1-28 or 1-21, rituximab (for CD20+ patients) IV on days 1 and 15, and methotrexate IT on days 1 and 15. Treatment repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with clinical benefit may continue to receive treatment for up to 12 months per the discretion of the physician. CONSOLIDATION CYCLES 4 AND 5 (ALL PATIENTS ONLY): Patients receive blinatumomab IV on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients continue to receive dasatinib PO QD and venetoclax PO QD as taken in cycles 1-3 and, if clinically indicated, methotrexate IT on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration, lumbar puncture, and blood sample collection throughout the study After completion of study treatment, patients are followed up at 4 weeks and then every 12 weeks for up to 1 year. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Not yet recruiting |
NCT03599869 -
Management of Mixed-Phenotype Acute Leukemia in the East of France
|
||
Recruiting |
NCT04067336 -
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT03959085 -
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
|
Phase 3 | |
Completed |
NCT02135874 -
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
|
Phase 2 | |
Suspended |
NCT03128034 -
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04065399 -
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT02921061 -
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
|
Phase 1/Phase 2 | |
Recruiting |
NCT05476770 -
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT04128501 -
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
|
Phase 2 | |
Recruiting |
NCT03957915 -
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
|
Early Phase 1 | |
Completed |
NCT05433532 -
Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
|
Phase 2 | |
Recruiting |
NCT03843528 -
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
|
Phase 1 | |
Active, not recruiting |
NCT05326516 -
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
|
Phase 1 | |
Recruiting |
NCT05457556 -
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
|
Phase 3 | |
Completed |
NCT00723099 -
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05316701 -
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
|
Phase 3 | |
Terminated |
NCT01887587 -
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
|
Phase 1 | |
Recruiting |
NCT04762485 -
Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT06013423 -
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
|
Phase 2 |